moxifloxacin has been researched along with Mycobacterium Infections in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Disratthakit, A; Doi, N | 1 |
| Al-Zubaidi, A; Cheung, CY; Cook, GM; Dawes, SS; Lott, JS; Mizrahi, V; Taiaroa, G | 1 |
| Chen, X; Fu, L; Lu, Y; Qi, X; Wang, B; Wang, H; Zhang, W; Zheng, L | 1 |
| Atsumi, T; Fujieda, Y; Iwasaki, N; Kamishima, T; Kono, M; Matsui, Y; Ninagawa, K | 1 |
| Fukao, A; Horikawa, S; Ikeue, T; Noguchi, S; Ohi, I; Sugita, T; Tanaka, E; Terashita, S; Yoshida, H | 1 |
| Brown-Elliott, BA; Chao, AS; Chiu, CH; Griffith, DE; Leu, HS; Lin, CS; Wu, TL; Wu, TS; Yang, CH | 1 |
| Govendir, M; Hansen, T; Malik, R; Nosworthy, P; Reppas, G | 1 |
| Bae, SM; Cheong, HJ; Choi, WS; Kim, MJ; Park, DW; Sohn, JW; Son, SW; Song, T; Yoon, YK | 1 |
| Culton, DA; Groben, P; Miller, M; Morrell, DS; Wertman, R | 1 |
| Choi, GE; Jeon, K; Koh, WJ; Min, KN; Shin, SJ; Won, CJ | 1 |
| LaBombardi, VJ; Shastry, L; Tischler, H | 1 |
11 other study(ies) available for moxifloxacin and Mycobacterium Infections
| Article | Year |
|---|---|
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity | 2010 |
RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Cell Death; Humans; Isoniazid; Moxifloxacin; Mycobacterium Infections; Mycobacterium tuberculosis; Rifampin; RNA; Streptomycin; Tuberculosis, Multidrug-Resistant | 2022 |
Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifabutin | 2023 |
Non-tuberculosis Mycobacterium Tenosynovitis with Rice Bodies in a Patient with Systemic Lupus Erythematosus.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Female; Fingers; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium Infections; Symptom Flare Up; Tenosynovitis | 2020 |
Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement.
Topics: Clarithromycin; Cough; Dyspnea; Exudates and Transudates; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections; Pleurisy; Tomography, X-Ray Computed | 2017 |
Postcesarean section wound infection caused by Mycobacterium massiliense.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Cesarean Section; Chaperonin 60; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Humans; Imipenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Mycobacterium Infections; Nontuberculous Mycobacteria; Pregnancy; Surgical Wound Infection; Teicoplanin | 2016 |
Inguinal panniculitis in a young Tasmanian devil (Sarcophilus harrisii) caused by Mycobacterium mageritense.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Doxycycline; Fluoroquinolones; Histocytochemistry; Male; Marsupialia; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Panniculitis; Quinolines; Subcutaneous Tissue | 2010 |
Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study.
Topics: Acupuncture Therapy; Amikacin; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Disease Outbreaks; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Korea; Male; Middle Aged; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Time Factors; Treatment Outcome | 2011 |
Mycobacterium bolletii/Mycobacterium massiliense furunculosis associated with pedicure footbaths: a report of 3 cases.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacterial Proteins; Baths; Chaperonin 60; Cosmetic Techniques; Female; Fluoroquinolones; Foot Dermatoses; Furunculosis; Humans; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Quinolines; Treatment Outcome; Young Adult | 2011 |
Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Female; Fluoroquinolones; Macrolides; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Quinolines | 2012 |
Mycobacterium thermoresistibile infection following knee-replacement surgery.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Aza Compounds; Doxycycline; Female; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Quinolines | 2005 |